Shahrokh Shabahang, D.D.S., M.S., Ph.D.


Dr. Shahrokh Shabahang co-founded SEKRIS with Dr. Alan Escher in 2009 to further develop and commercialize a technology designed for induction of tolerance to self and transplanted tissues. Since then, he has helped assemble a team of experts in autoimmune diseases, transplant immunology and biopharmaceutical product development.

Dr. Shabahang has also created key collaborations with contract research organizations, top academic institutions and financial institutions to expand the breath of applications of SEKRIS technology and to secure the necessary resources to bring the technology to the clinic.

His vision is to translate the basic discoveries that were made in the laboratory to clinical products that enable people living with inflammatory disorders to lead a free and independent life.

Alan P. Escher,  Ph.D.


Dr. Alan Escher received his BSc magna cum laude from the University of Connecticut and PhD from Cornell University.

Dr. Escher was previously Associate Professor and Associate Director of the Center for Transplant Immunology Research at the Loma Linda University School of Medicine, where he and his colleagues started to develop pro-apoptotic DNA vaccination for the treatment of type 1 diabetes. His laboratory was among the first to report the beneficial effects of DNA vaccination for type 1 diabetes in 1999. Later, his team successfully translated the technology to prevention of skin allograft rejection as proof-of-concept for application to organ transplantation.

In 2009, he began his transition from the academic setting. He co-founded SEKRIS Biomedical to translate apoptotic DNA immunotherapy for treatment of inflammatory disorders. As Executive Vice President of Technology Development, he continued to strengthen the patent portfolio.

While his presence will be sorely missed, Dr. Escher’s legacy will continue through continued development of his work and realization of his vision to control unwanted inflammation with the ADI technology.